Losartan-induced Ischemic Hepatocellular Hepatotoxicity: A Case Report and Literature Review.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 25374869.
- Also identified by DOI 10.4103/2249-4863.141635 and PMC identifier PMC27470.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
With the increasing use of various medications and supplements nowadays, the incidence of abnormal liver function tests and frank hepatic injury is has been increasing. Medications are now considered one of the most common causes of acute hepatic failure in the United States. Losartan was the first angiotensin 1 (AT1) receptor blocker approved by FDA for the treatment of arterial hypertension. It is a well-tolerated medication with few significant adverse effects. However, losartan-related hepatotoxicity has been reported rarely. We report a case of acute hepatic injury in an adult patient treated with losartan as a monotherapy for arterial hypertension.